A different perspective into clinical symptoms in CPT I deficiency

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Carnitine palmitoyltransferase I (CPT I) deficiency is an inherited metabolic disorder affecting fatty acid oxidation.
• It is characterized by episodes of metabolic decompensation, including hypoketotic hypoglycemia, hepatomegaly, seizures, and hyperammonemia.

Purpose of the Study:

• To investigate the spectrum of neurological symptoms in CPT I deficiency.
• To identify predisposing factors for neurological sequelae.
• To highlight the importance of neurological evaluation in managing CPT I deficiency.

Main Methods:

• Retrospective review of clinical data from 14 patients with CPT I deficiency.
• Analysis of presenting symptoms and neurological findings during a mean follow-up of 10.3 years.

Main Results:

• The study identified a wide range of neurological symptoms, with psychomotor retardation, seizures, and encephalopathy being common presenting symptoms.
• Speech disorders were prevalent, affecting 9 out of 14 patients, and included delayed language development and articulation difficulties.
• Abnormal cranial MRI findings and attention deficit hyperactivity disorder were also noted.

Conclusions:

• CPT I deficiency presents with broader neurological manifestations than previously recognized, particularly significant speech disorders.
• Early diagnosis and prompt treatment are essential to mitigate neurological sequelae.
• Comprehensive neurological assessment at diagnosis and throughout follow-up is critical for patients with CPT I deficiency.